Lung cancer culprit could offer therapeutic target
September 14th, 2010 - 3:05 pm ICT by ANIWashington, Sep 14 (ANI): New research has suggested that a tiny molecule, which spurs the progression of lung cancer, could become a key player in fighting the disease.
Scientists have known that the molecule microRNA-21, or miR-21, is present in overabundant quantities in human tumors, including non-small-cell lung cancer (NSCLC).
Until now, however, it was unclear whether miR-21 contributed to the development of lung cancer, or whether it was simply an indicator of the presence of the disease.
To find out, lead study author Dr. Mark Hatley, an instructor of pediatric hematology/oncology, and UT Southwestern colleagues used mice that had been altered specifically to harbor non-small-cell lung cancer.
In some of these mice, they genetically engineered the animals to produce too much miR-21. In another group, they deleted the miR-21 gene altogether, which eliminated the molecule in the rodents.
In animals with cancer, the results showed that too much miR-21, or overexpression, promotes the formation, growth and survival of new tumors by turning off certain genes that normally allow cancer cells to die.
In fact, at 18 weeks of age, the study group with overexpressed miR-21 had significantly more tumors than their lung-cancer-carrying littermates with normal levels of miR-21. Healthy rodents engineered to overexpress miR-21 did not develop cancer.
“These results indicate that overexpression of miR-21 alone is not enough to initiate tumors in a healthy animal. Instead, it appears that miR-21 enhances the growth and survival of existing lung cancer,” said Dr. Hatley, a Pediatric Scientist Development Program fellow.
Dr. Eric Olson, chairman of molecular biology at UT Southwestern and the study’s senior author, said the experiments also show that deleting miR-21 sensitizes the animals’ cancer cells to a certain kind of chemotherapy, suggesting that inhibiting miR-21 in lung-cancer patients could be of therapeutic value.
“More research will be needed before we know whether this is applicable to humans, but it’s possible that a drug designed to inhibit miR-21 could help keep cancer at bay,” he added. (ANI)
- Key step in body's ability to make red blood cells found - Aug 01, 2010
- Genetic change helps lung tumors spread to other parts of the body - Apr 07, 2011
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- RNA-based drugs may prevent premature labour - Nov 16, 2010
- Micro-RNA decides malignancy of lung cancer - Sep 09, 2010
- New targets for treatment of invasive breast cancer identified - Aug 20, 2009
- Key component in the spread of lung cancer discovered - Mar 15, 2011
- New discovery may help in the fight against ovarian cancer - Feb 04, 2011
- Protein that thwarts tumor invasion uncovered - Jun 06, 2010
- New discovery shows promise against pancreatic cancer - Dec 16, 2010
- Scientists make breakthrough in small-cell lung cancer - Jan 14, 2010
- Overabundance of protein promotes growth of breast cancer stem cells - Feb 16, 2011
- Function of novel molecule that underlies human deafness revealed - Jan 22, 2011
- Turning off oncogene may inhibit lung cancer stem cells' growth - Sep 09, 2009
- Brain tumour's 'grow-or-go' switch found - Mar 12, 2010
Tags: cancer cells, cell lung cancer, dr eric, eric olson, formation growth, human tumors, lung cancer, lung cancer patients, molecular biology, non small cell lung cancer, nsclc, overexpression, pediatric hematology oncology, program fellow, small cell lung cancer, study author, target washington, therapeutic target, therapeutic value, tiny molecule